Voyager to Present at Upcoming Investor Conferences

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a leading biotechnology company focused on innovative genetic therapies for neurological diseases, has announced its upcoming participation in several investor conferences in September 2025. These engagements include notable events in Boston and New York where the company aims to showcase its advanced research and development efforts.

The series of conferences begins with the Citi's 2025 Biopharma Back to School Conference, where Voyager will host a fireside chat on September 2 at 4:00 p.m. ET. During this session, the company will present preclinical data that emphasizes its non-viral delivery platform, which utilizes novel receptor-binding molecules to facilitate the transport of multiple neurotherapeutic modalities across the blood-brain barrier.

Following this, Voyager will partake in the Wells Fargo Healthcare Conference on September 3 and the Cantor Global Healthcare Conference on September 4, both featuring additional fireside chats. Subsequent to these events, the company will hold one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, before concluding its conference schedule at the Baird 2025 Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference on September 9.

Investors and interested parties will have the opportunity to access webcasts from the Citi and Baird fireside chats on Voyager’s website, with recordings available for at least 30 days.

Voyager's current pipeline includes therapies targeting various neurological conditions, including Alzheimer's disease, Parkinson's disease, and ALS, leveraging its proprietary TRACER™ AAV capsid discovery platform. With collaborations involving major partners like Alexion and Novartis, Voyager reaffirms its commitment to pioneering treatments that could significantly alter the treatment landscape for central nervous system disorders.

As Voyager Therapeutics (Nasdaq: VYGR) prepares for several key investor conferences in early September 2025, this is an opportune moment for current and potential investors to reassess their positions. The company is positioning itself as a leader in genetic therapies for neurological diseases, showcasing its innovative non-viral delivery platform that utilizes receptor-binding molecules to traverse the blood-brain barrier. This technology could significantly enhance the efficacy of neurotherapeutics, which is a promising avenue considering the limited treatment options available for such diseases.

Investors should focus on the types of data and potential advancements that Voyager aims to present during these conferences. The emphasis on preclinical data regarding their TRACER™ AAV capsid discovery platform could attract attention from institutional investors looking for cutting-edge biotechnology initiatives. With collaborations alongside industry heavyweights like Alexion and Novartis, the validation from these partnerships suggests that Voyager's therapeutic approaches are taken seriously within the broader pharmaceutical landscape.

Moreover, the timing aligns closely with a continual influx of investment in biotech, particularly in genetics and neurology. With neurological disorders affecting millions globally and an increase in funding for research, Voyager is well-positioned to leverage this market demand.

Concisely, investors should monitor Voyager's presentations carefully, assessing not only the data and questions from analysts but also market reactions that may ensue. A successful engagement at these conferences may boost the stock momentum, but caution should be exercised. The volatile nature of biotech stocks necessitates that potential investments be made with a full understanding of the associated risks, particularly given the demands for rigorous clinical data before any therapeutic product reaches the market.